Vir Biotechnology (VIR) Non-Current Deferred Tax Liability (2018 - 2023)

Vir Biotechnology has reported Non-Current Deferred Tax Liability for 6 years, with the latest figure at $3.3 million in Q1 2023.

• Quarterly Non-Current Deferred Tax Liability fell 82.36% year-over-year to $3.3 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $3.3 million (down 82.36% YoY) and the FY2022 annual result came in at $3.3 million, down 82.36% from the prior year.
• Non-Current Deferred Tax Liability held at $3.3 million in Q1 2023 per VIR's latest filing, from $3.3 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $18.4 million in Q4 2021 and troughed at $3.3 million in Q4 2020.
• A 5-year average of $7.3 million and a median of $3.3 million in 2019 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2021 and 2022: Non-Current Deferred Tax Liability jumped 466.83% in 2021, then plunged 82.36% in 2022.
• Over 5 years, Non-Current Deferred Tax Liability stood at $3.3 million in 2019, then declined by 1.57% to $3.3 million in 2020, then surged by 466.83% to $18.4 million in 2021, then slumped by 82.36% to $3.3 million in 2022, then changed by 0.0% to $3.3 million in 2023.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $3.3 million, $3.3 million, and $18.4 million for Q1 2023, Q4 2022, and Q3 2022 respectively.